α-Aminooxyacetic acid derivatives acting as pro-drugs againstMycobacterium tuberculosis

Author:

Vill Kristin,van Geelen Lasse,Michel Oliver,Kiffe-Delf Anna-Lene,Berger Alexander,Podlesainski David,Stenzel Katharina,Kovacic FilipORCID,Lungerich Beate,Burkhardt Björn,Crooks Taylor A.,Howe Michael D.,Ostrer Lev,Jia Ziyi,Ioerger Thomas R.,Kaschani Farnusch,Kaiser MarkusORCID,Baughn Anthony D.,Kurz Thomas,Kalscheuer RainerORCID

Abstract

ABSTRACTTuberculosis (TB), a significant cause of mortality globally, continues to claim 1.5 million lives each year. Despite recent advances in TB management, the emergence of multidrug-resistant strains of TB is exacerbating the treatment of TB. Therefore, there is an immediate necessity to uncover new anti-TB compounds with unprecedented targets. This study introduces novel antimycobacterial molecules that are based on α-aminooxyacetic acid core structures. The lead compounds KSK-104 and KSK-106 displayed potent sub-micromolar antibacterial activity againstMycobacterium tuberculosisH37Rv and XDR clinical isolates, while exhibiting virtually no cytotoxicity against various human cells. Complementation experiments following whole genome sequencing of spontaneously resistant mutants generated against these bactericidal compounds suggested that they are pro-drugs that are intracellularly hydrolyzed by one or both of two specific amidohydrolases, Rv0552 and AmiC. Furthermore, proteomic and transcriptomic analyses of stressed cells and genetic interaction mapping employing transposon insertion sequencing suggest a “dirty drug” mechanism that involves the simultaneous attack of the various drug cleavage products on multiple intracellular targets. Our results suggest a primary role of the pyridoxal 5’-phosphate (PLP) synthesis and salvage pathway and/or PLP-dependent enzymes, the oxidative stress network, and the largely uncharacterizedRv3092c-Rv3095gene cluster in the mode of action.

Publisher

Cold Spring Harbor Laboratory

Reference77 articles.

1. World Health Organization (2022). Global tuberculosis report 2022.

2. The Diagnosis and Therapy of Tuberculosis During the Past 100 Years

3. World Health, O. (2018). Rapid сommunication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). World Health Organization.

4. The present state of the tuberculosis drug development pipeline

5. Current and future treatments for tuberculosis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3